Your browser doesn't support javascript.
loading
The effect of education regarding treatment guidelines for schizophrenia and major depressive disorders on psychiatrists' hypnotic medication prescribing behavior: a multicenter study.
Nakamura, Toshinori; Furihata, Ryuji; Hasegawa, Naomi; Kodaka, Fumitoshi; Muraoka, Hiroyuki; Ichihashi, Kayo; Ochi, Shinichiro; Numata, Shusuke; Tsuboi, Takashi; Makinodan, Manabu; Iida, Hitoshi; Onitsuka, Toshiaki; Kashiwagi, Hiroko; Takeshima, Masahiro; Hashimoto, Naoki; Nagasawa, Tatsuya; Usami, Masahide; Yamagata, Hirotaka; Takaesu, Yoshikazu; Miura, Kenichiro; Matsumoto, Junya; Ohi, Kazutaka; Yamada, Hisashi; Hori, Hikaru; Inada, Ken; Watanabe, Koichiro; Hashimoto, Ryota; Yasui-Furukori, Norio.
Afiliación
  • Nakamura T; Department of Psychiatry, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
  • Furihata R; Agency for Student Support and Disability Resources, Kyoto University, Yoshida-Honmachi, Kyoto, 606-8501, Japan.
  • Hasegawa N; Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, 187-8553, Japan.
  • Kodaka F; Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, 187-8553, Japan.
  • Muraoka H; Department of Psychiatry, The Jikei University School of Medicine, 3-18-13 Nishi-Shinbashi, Minato, 105-8471, Japan.
  • Ichihashi K; Department of Psychiatry, Kitasato University School of Medicine, 1-15-1 Kitazato, Sagamihara, 252-0373, Japan.
  • Ochi S; Department of Neuropsychiatry, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo, 113-8655, Japan.
  • Numata S; Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Shitsukawa, Toon, 791-0295, Japan.
  • Tsuboi T; Department of Psychiatry, Graduate School of Biomedical Science, Tokushima University, 3-8-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
  • Makinodan M; Department of Neuropsychiatry, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, 181-8611, Japan.
  • Iida H; Department of Psychiatry, Nara Medical University, 840 Shijo-cho, Kashihara, 634-8522, Japan.
  • Onitsuka T; Department of Psychiatry, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Fukuoka, 814-0180, Japan.
  • Kashiwagi H; NHO Sakakibara National Hospital, 777 Sakakibara-cho, Tsu, 514-1292, Japan.
  • Takeshima M; Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, 187-8553, Japan.
  • Hashimoto N; Department of Forensic Psychiatry, National Center Hospital, National Center of Psychiatry and Neurology, 4-1-1 Ogawahigashi, Kodaira, 187-8551, Japan.
  • Nagasawa T; Department of Neuropsychiatry, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
  • Usami M; Department of Psychiatry, Hokkaido University Graduate School of Medicine, Kita 15 Nishi 7, Sapporo, 060-8638, Japan.
  • Yamagata H; Department of Neuropsychiatry, Kanazawa Medical University, 1-1 Daigaku, Uchinada, 920-0293, Japan.
  • Takaesu Y; Department of Child and Adolescent Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, 272-8516, Japan.
  • Miura K; Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, 187-8553, Japan.
  • Matsumoto J; Kokoro Hospital Machida, 2140 Kamioyamadamachi, Machida, Japan.
  • Ohi K; Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, 903-0215, Japan.
  • Yamada H; Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, 187-8553, Japan.
  • Hori H; Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, 187-8553, Japan.
  • Inada K; Department of Psychiatry, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan.
  • Watanabe K; Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, 187-8553, Japan.
  • Hashimoto R; Department of Neuropsychiatry, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan.
  • Yasui-Furukori N; Department of Psychiatry, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Fukuoka, 814-0180, Japan.
BMC Psychiatry ; 24(1): 399, 2024 May 29.
Article en En | MEDLINE | ID: mdl-38807065
ABSTRACT

BACKGROUND:

To examine whether the "Effectiveness of Guideline for Dissemination and Education in psychiatric treatment (EGIUDE)" project affects the rate of prescriptions of hypnotic medication and the type of hypnotic medications prescribed among psychiatrists, for schizophrenia and major depressive disorder in Japan.

METHODS:

The EGUIDE project is a nationwide prospective study of evidence-based clinical guidelines for schizophrenia and major depressive disorder in Japan. From 2016 to 2021, clinical and prescribing data from patients discharged from hospitals participating in the EGUIDE project were used to examine hypnotic medication prescriptions The prescribing rate of hypnotics and the prescribing rate of each type of hypnotic (benzodiazepine receptor agonist, nonbenzodiazepine receptor agonist, melatonin receptor agonist, and orexin receptor antagonist) were compared among patients who had been prescribed medication by psychiatrists participating in the EGUIDE project and patients who had been prescribed medication by nonparticipating psychiatrists. Multivariate logistic regression analysis was performed to examine the effect of the EGUIDE project on the prescription of hypnotic medications.

RESULTS:

A total of 12,161 patients with schizophrenia and 6,167 patients with major depressive disorder were included. Psychiatrists participating in the EGUIDE project significantly reduced the rate of prescribing hypnotic medication and benzodiazepine receptor agonists for both schizophrenia (P < 0.001) and major depressive disorder (P < 0.001) patients.

CONCLUSION:

This is the first study to investigate the educational effects of guidelines for the treatment of psychiatric disorders on psychiatrists in terms of prescribing hypnotic medications to patients. The EGUIDE project may play an important role in reducing hypnotic medication prescription rates, particularly with respect to benzodiazepine receptor agonists. The results suggest that the EGUIDE project may result in improved therapeutic behavior.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esquizofrenia / Pautas de la Práctica en Medicina / Guías de Práctica Clínica como Asunto / Trastorno Depresivo Mayor / Hipnóticos y Sedantes Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: BMC Psychiatry Asunto de la revista: PSIQUIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Esquizofrenia / Pautas de la Práctica en Medicina / Guías de Práctica Clínica como Asunto / Trastorno Depresivo Mayor / Hipnóticos y Sedantes Límite: Adult / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: BMC Psychiatry Asunto de la revista: PSIQUIATRIA Año: 2024 Tipo del documento: Article País de afiliación: Japón